GlassScriptPhysician profile
Khurram I Ashraf
NPI 1811991508
$7,826.15
in general payments reported to CMS, 2019-2025
29 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,918 · 2020: $96.65 · 2021: $471 · 2022: $663 · 2023: $713 · 2024: $559 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $4,006.00 | 2019 | |
| Abbvie INC. | $1,507.87 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Boston Scientific Corporation | $416.62 | 2019-2023 | Exalt Model D, Acquire |
| Pfizer INC. | $275.98 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $185.05 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $171.49 | 2021-2025 | Linzess |
| Ferring Pharmaceuticals INC. | $161.80 | 2019-2025 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.09 | 2019-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $124.56 | 2019-2023 | Gattex |
| Lilly USA, LLC | $98.53 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $87.61 | 2019-2022 | |
| Romark Laboratories, Lc | $83.53 | 2019 | |
| Ardelyx, INC. | $81.98 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $80.97 | 2023-2025 | |
| Janssen Biotech, INC. | $71.62 | 2021-2023 | Stelara |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $58.16 | 2022-2023 | Zeposia |
| Organon LLC | $49.62 | 2023 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $41.58 | 2022-2024 | Dificid |
| Cook Medical LLC | $28.31 | 2019 | |
| Capsovision, INC. | $17.49 | 2024 | Capsocam Plus |
| Gilead Sciences, INC. | $17.48 | 2025 | |
| Olympus America INC. | $17.34 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.76 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.91 | 2022 | |
| Curium US LLC | $12.92 | 2022 | |
| Medtronic USA, INC. | $12.70 | 2019 | |
| Qol Medical, LLC | $12.16 | 2021 | |
| Novo Nordisk INC | $11.76 | 2021 | |
| Currax Pharmaceuticals LLC | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.